Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tazobactam sodium, quantity: 536.6 mg (equivalent: tazobactam, qty mg); piperacillin sodium, quantity: 4.17 g (equivalent: piperacillin, qty g) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - piperacillin sodium, quantity: 2.085 g (equivalent: piperacillin, qty g); tazobactam sodium, quantity: 268.3 mg (equivalent: tazobactam, qty mg) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - sodium chloride 9 g/l;  ;  ;  ;  ;   - solution for infusion - 0.9 % - active: sodium chloride 9 g/l           excipient: hydrochloric acid sodium hydroxide water for injection - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - sodium chloride 0.9%;  ;   - solution for injection - 0.9 % - active: sodium chloride 0.9%     excipient: hydrochloric acid sodium hydroxide water for injection - sodium chloride injection bp 0.9% can be used as the vehicle for the restoration of electrolytes, as the vehicle for parenteral drug administration or as a sterile irrigation medium.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanine 16 g/l;  ;  ;  ; arginine 11.3 g/l;  ;  ; aspartic acid 3.4 g/l;  ;  ; glutamic acid 5.6 g/l;  ;  ; glycyl-l-glutamine 30.27 g/l;  ; glycyl-l-tyrosine 3.45 g/l; histidine 6.8 g/l;  ;  ; isoleucine 5.6 g/l;  ;  ;  ; leucine 7.9 g/l;  ;  ;  ; lysine acetate 12.7 g/l;  ;  ;  ; methionine 5.6 g/l;  ; phenylalanine 5.85 g/l;  ;  ;  ;  ; proline 6.8 g/l;  ; serine 4.5 g/l;  ;  ;  ; threonine 5.6 g/l;  ;  ;  ; tryptophan 1.9 g/l;  ;  ; valine 7.3 g/l;  ;   - solution for infusion - 134 g/l - active: alanine 16 g/l       arginine 11.3 g/l     aspartic acid 3.4 g/l     glutamic acid 5.6 g/l     glycyl-l-glutamine 30.27 g/l   glycyl-l-tyrosine 3.45 g/l histidine 6.8 g/l     isoleucine 5.6 g/l       leucine 7.9 g/l       lysine acetate 12.7 g/l       methionine 5.6 g/l   phenylalanine 5.85 g/l         proline 6.8 g/l   serine 4.5 g/l       threonine 5.6 g/l       tryptophan 1.9 g/l     valine 7.3 g/l     excipient: citric acid monohydrate water for injection - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate to severe catabolic status.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - biotin 60ug;  ; cyanocobalamin 5ug; folic acid 0.4mg; nicotinamide 40mg; pyridoxine hydrochloride 4.9mg;  ; riboflavin sodium phosphate 4.9mg; sodium ascorbate 113mg; sodium pantothenate 16.5mg; thiamine nitrate 3.1mg - powder for injection - active: biotin 60ug   cyanocobalamin 5ug folic acid 0.4mg nicotinamide 40mg pyridoxine hydrochloride 4.9mg   riboflavin sodium phosphate 4.9mg sodium ascorbate 113mg sodium pantothenate 16.5mg thiamine nitrate 3.1mg excipient: glycine methyl hydroxybenzoate sodium edetate - supplement in intravenous nutrition in order to meet the daily requirements of the water-soluble vitamins in adults, children, infants and neonates. fat-soluble vitamins should also be administered to patients receiving prolonged parenteral nutrition.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 60 g/l; magnesium chloride hexahydrate 0.3 g/l;  ; potassium chloride 0.3 g/l; sodium acetate trihydrate 4.63 g/l;  ; sodium chloride 6.02 g/l;  ;  ;   - solution for infusion - 6 % - active: hydroxyethyl starch 130/0.4 60 g/l magnesium chloride hexahydrate 0.3 g/l   potassium chloride 0.3 g/l sodium acetate trihydrate 4.63 g/l   sodium chloride 6.02 g/l       excipient: hydrochloric acid sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - calcium chloride dihydrate 0.27 g;  ;  ;  ;  ; potassium chloride 0.4 g;  ;  ;  ; sodium chloride 6 g;  ;  ;  ;  ;  ; sodium lactate 3.17 g (as 6.34g sodium lactate solution 50%);   - solution for infusion - active: calcium chloride dihydrate 0.27 g         potassium chloride 0.4 g       sodium chloride 6 g           sodium lactate 3.17 g (as 6.34g sodium lactate solution 50%)   excipient: hydrochloric acid sodium hydroxide water for injection - compound sodium lactate (hartmann's) is used for intravenous fluid and electrolyte replacement.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanylglutamine 200 mg/ml;  ;   - concentrate for infusion - 200 mg/ml - active: alanylglutamine 200 mg/ml     excipient: nitrogen water for injection - dipeptiven® is indicated as part of a clinical nutrition regimen in patients in hypercatabolic and/or hypermetabolic states. it should be given together with parenteral or enteral nutrition or a combination of both.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - propofol 10 mg/ml;   - emulsion for injection - 1 % - active: propofol 10 mg/ml   excipient: egg lecithin glycerol medium-chain triglycerides nitrogen oleic acid sodium hydroxide soya oil water for injection - · induction of general anaesthesia in children and adults: fresofol 1% mct/lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older. · maintenance of general anaesthesia in children and adults: fresofol 1% mct/lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older. fresofol 1% mct/lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided. fresofol 1% mct/lct has no analgesic properties. · sedation during intensive care in adults: fresofol 1% mct/lct may also be used in adults for sedation of ventilated patients receiving intensive care. · conscious sedation for surgical and diagnostic procedures in adults: fresofol 1% mct/lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.